Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calamine + zinc oxide is an approved topical combination drug developed by Laboratoires Bailleul (a subsidiary of Laboratoires de Monaco) for the treatment of skin irritations. Formulated as a gel containing 8% calamine and 8% zinc oxide, it acts through physical and chemical mechanisms on the skin surface without a specific molecular biological target. Zinc oxide serves as an anti-inflammatory and skin-protective agent, forming a barrier that reduces irritation and promotes skin regeneration, while calamine provides soothing and antipruritic (anti-itch) effects. It is approved as an over-the-counter adjunct treatment for irritant dermatitis, and is also used to relieve symptoms associated with chickenpox, insect bites, superficial burns, and other skin irritations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calamine + zinc oxide.